Halozyme Therapeutics (HALO) Tops Q2 EPS by 6c

August 9, 2016 4:12 PM EDT

Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.

Halozyme Therapeutics (NASDAQ: HALO) reported Q2 EPS of ($0.21), $0.06 better than the analyst estimate of ($0.27). Revenue for the quarter came in at $33.3 million versus the consensus estimate of $29.94 million.


Halozyme Therapeutics sees FY2016 revenue of $140-150 million, versus prior guidance of $130-145 million and the consensus of $136.7 million.

For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Earnings, Guidance

Related Entities


Add Your Comment